K. Lauritsen - Publications, H-index & Citations

K. Lauritsen

University of Southern Denmark

42H指数

168论文数

6.7K被引数

收录论文 22

发表时间

Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - results from the STARS II study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2011-08-17

OAAI

van Zanten, S. Veldhuyzen; Wahlqvist, P.; Talley, N. J.; Halling, K.; Vakil, N.; Lauritsen, K.; Flook, N.; Persson, T.; Bolling-Sternevald, E.

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2008-07-07

162

OAAI

Talley, NJ; Lauritsen, K; Tunturi-Hihnala, H; Lind, T; Moum, B; Bang, C; Schulz, T; Omland, TM; Delle, M; Junghard, O

Randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

IF12

2007-12-01

OAAI

Kahrilas, Peter J.; Dent, John; Lauritsen, Karsten; Malfertheiner, Peter; Denison, Hans; Franzen, Stefan; Hasselgren, Goran

Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2007-06-16

OAAI

Talley, N. J.; Vakil, N.; Lauritsen, K.; Van Zanten, S. V.; Flook, N.; Bolling-Sternevald, E.; Persson, T.; Bjorck, E.; Lind, T.

One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2007-06-16

PREAI

Van Zanten, S. V.; Flook, N.; Talley, N. J.; Vakil, N.; Lauritsen, K.; Bolling-Sternevald, E.; Persson, T.; Bjorck, E.; Svedberg, L.-E.

Esomeprazole treatment in patients with uninvestigated non-GERD dyspepsia leads to significant improvements in productivity while at work and in daily activities - Results from a randomised, placebo-controlled clinical study

VALUE IN HEALTH

IF6

2005-11-01

OAAI

Wahlqvist, P; Bergenheim, K; Persson, T; Brun, J; Flook, N; Lauritsen, K; Vakil, N; van Zanten, SV; Zanten, S; Talley, NJ

Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis:: results from the EXPO study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2005-10-14

PREAI

Labenz, J; Armstrong, D; Lauritsen, K; Katelaris, P; Schmidt, S; Schütze, K; Wallner, G; Juergens, H; Preiksaitis, H; Keeling, N; Nauclér, E; Adler, J; Eklund, S

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis:: the EXPO study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2005-03-15

119

OAAI

Labenz, J; Armstrong, D; Lauritsen, K; Katelaris, P; Schmidt, S; Schütze, K; Wallner, G; Juergens, H; Preiksaitis, H; Keeling, N; Nauclér, E; Eklund, S

The role of acid suppression in patients with endoscopy-negative reflux disease:: the effect of treatment with esomeprazole or omeprazole

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2004-07-26

PREAI

Armstrong, D; Talley, NJ; Lauritsen, K; Moum, B; Lind, T; Tunturi-Hihnala, H; Venables, T; Green, J; Bigard, MA; Mössner, J; Junghard, O

Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2003-07-07

PREAI

Bolling-Sternevald, E; Lauritsen, K; Talley, NJ; Junghard, O; Glise, H

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis:: Metropole study results

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2003-03-11

OAAI

Lauritsen, K; Devière, J; Bigard, MA; Bayerdörffer, E; Mózsik, G; Murray, F; Kristjánsdóttir, S; Savarino, V; Vetvik, K; De Freitas, D; Orive, V; Rodrigo, L; Fried, M; Morris, J; Schneider, H; Eklund, S; Larkö, A

Dose finding study of mosapride in functional dyspepsia:: a placebo-controlled, randomized study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2002-04-27

OAAI

Hallerbäck, BI; Bommelaer, G; Bredberg, E; Campbell, M; Hellblom, M; Lauritsen, K; Wienbeck, M; Holmgren, LL

Epidemiology of NSAID-related gastroduodenal mucosal injury

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY

IF4

2001-10-01

PREAI

Aalykke, C; Lauritsen, K

Gastrointestinal (GI) symptoms, quality of life and endoscopic diagnoses in patients with upper GI symptoms

GASTROENTEROLOGY

IF25.1

2001-04-01

PREAI

Bolling-Sternevald, E; Carlsson, R; Aalykke, C; Wilson, B; Junghard, O; Lauritsen, K; Glise, H

7-day triple triple with esomeprazole, amoxicillin and clarithromycin for H-pylori (H P) eradication in duodenal ulcer (DU) disease.

GASTROENTEROLOGY

IF25.1

2000-04-01

PREAI

van Zanten, SJV; Lauritsen, K; Delchier, JC; Labenz, J; de Argila, CM; Lind, T; Treichel, HC; Stubberod, A; Cockeran, AW; Hasselgren, G; Gothe, L; Wrangstadh, M

Efficacy of pantoprazole compared with omeprazole in prevention of relapse of reflux esophagitis: Double-blind, randomized multicenter trial.

GASTROENTEROLOGY

IF25.1

2000-04-01

PREAI

Lauritsen, K; Jaup, B; Carling, L; Raptis, S; Aadland, E; Farkkila, M; Elawaut, A; Krejs, G; Altorfer, J

Role of NSAID use in inflammatory bowel disease. A 5-year follow-up study.

GASTROENTEROLOGY

IF25.1

2000-04-01

OAAI

Aalykke, C; Hallas, J; Lauritsen, JM; Lauritsen, K